301246 宏源药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入703,52662.31%1,939,4691,770,7242,054,8822,063,723
减:营业总成本543,86630.48%1,794,9181,712,6791,965,2811,747,886
    其中:营业成本478,38127.03%1,575,3191,554,9571,788,0141,582,385
               财务费用3,544-3,099.49%10,239(2,968)(3,394)(10,963)
               资产减值损失(3,806)-64.09%(40,088)(34,813)(26,380)(39,157)
公允价值变动收益1,470-60.79%1,8493,8182,860--
投资收益23,263-1,424.38%31,0653,05319,420170,001
    其中:对联营企业和合营企业的投资收益19,406-553.11%7,732(25,378)(8,142)169,142
营业利润183,6271,398.26%158,26760,045105,645479,934
利润总额164,8661,303.18%145,71559,69198,558477,976
减:所得税费用20,668606.34%28,0858,22911,38943,181
净利润144,1981,534.26%117,63051,46287,169434,796
减:非控股权益(150)139.35%(1,424)(3)----
股东净利润144,3481,524.43%119,05351,46587,169434,796

市场价值指针
每股收益 (元) *0.3641,524.11%0.3000.1290.2251.233
每股派息 (元) *----0.0500.0300.0500.100
每股净资产 (元) *11.5215.77%11.14910.90210.8995.992
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容